Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "amgen rank"

Amgen updates on Prolia in postmenopausal osteoporosis16-09-2014
Pharma Letter

Amgen Posts Results from Exploratory Analyses Evaluating Long-...

According to a release from the Company, Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Data were presented at the American Society for Bone and Mineral ..., 1 month ago

1 images for "amgen rank"

AdvisorOne, 5 days ago

Amgen Up on Strategic Initiatives and 2015 Guidance

Amgen ( AMGN ) shares gained 6.1% immediately after the company held a business review meeting and provided a comprehensive overview of its initiatives geared towards growth objectives, and strategic and capital allocation plans. Amgen also provided ...
 Yahoo! Finance20 hours ago

Amgen Beats on Q3 Earnings & Revenues, Ups View Again

Amgen ( AMGN ) reported third quarter 2014 earnings of $2.30 per share, well above the Zacks Consensus Estimate of $2.06 and the year-ago earnings of $1.93. Earnings were driven by higher revenues and higher profitability on Enbrel. [embedded ...
 Yahoo! Finance2 days ago

Amgen Beats Earnings Estimates, What's Next for AMGN?

Earlier today, the world's largest biotechnology company, Amgen Inc. ( AMGN ) reported its earnings results for fiscal Q3 after the closing bell, and the company posted better than anticipated earnings and revenue, despite the fact that the ...
 Yahoo! Finance2 days ago

Amgen And Regeneron Reach All-Time Highs Together: Updates On Both Biotech Stalwarts

Summary Amgen and Regeneron are the two companies that have filed for marketing approval for their drugs to lower cholesterol via the PCSK9 pathway. Each company has numerous strengths. Recent data have given additional force to the uptrends of ...
 Seeking Alpha1 week ago Amgen Sues Sanofi and Regeneron over PCSK9 Candidate  Yahoo! Finance1 week ago

Daniel Loeb urges Amgen to split into two companies

(REUTERS) Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent. Our own extensive ...
 Fortune1 week ago UPDATE 2-Third Point's Loeb urges breakup of biotech company Amgen  CNBC1 week ago Loeb's hedge fund Third Point bets on eBay, Amgen, Alibaba, exits Sony  GlobalPost1 week ago Third Point's Loeb urges breakup of biotech company Amgen  Yahoo! Finance1 week ago

The Zacks Analyst Blog Highlights:Celgene, Biogen, Alexion, Cubist and Amgen

Today, Zacks is promoting its ''Buy'' stock recommendations. . Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup It was all about earnings last week with several biotech companies reporting third quarter results. While it ...
 Wall Street Select1 hour ago THE ZACKS ANALYST BLOG HIGHLIGHTS : Celgene, Biogen, Alexion, Cubist and Amgen  4 Traders1 hour ago The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics  Yahoo! Finance1 week ago The Zacks Analyst Blog Highlights:Auxilium, Gilead, AbbVie, Amgen and Alnylam  MoneyShow.com2 weeks ago

Will Amgen (AMGN) Disappoint in the Q3 Earnings Season?

Amgen Inc. ( AMGN ) is set to report third-quarter 2014 results on Oct 27 after the market closes. Last quarter, the company had posted a positive earnings surprise of 19.10%. The company recorded positive earnings surprises in the last four ...
 Yahoo! Finance5 days ago Stock of the Week: Amgen Inc. (AMGN)  Nasdaq3 weeks ago

Potential Amgen (AMGN) Trade Has 2.31% Downside Protection

( via COMTEX) -- With bearish technical indicators and a 4 STARS (out of 5) buy ranking from Standard & PooraEUR(TM)s, Amgen Inc ( AMGN ) could be an attractive play for investors according to ...
 TradingCharts.com2 weeks ago Potential Amgen (AMGN) Trade Targets 7.54% Return  Individual.com3 weeks ago

Amgen Files Blinatumomab Marketing Application in U.S.

Amgen ( AMGN ) announced that it has submitted a Biologics License Application (:BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from ...
 Yahoo! Finance1 month ago Amgen One Step Closer To Immunotherapy Market  Bidness Etc1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less